C
Christopher S. Breivogel
Researcher at Campbell University
Publications - 19
Citations - 1530
Christopher S. Breivogel is an academic researcher from Campbell University. The author has contributed to research in topics: Cannabinoid receptor & Cannabinoid. The author has an hindex of 12, co-authored 18 publications receiving 1448 citations.
Papers
More filters
Journal ArticleDOI
Cannabinoid physiology and pharmacology: 30 years of progress
Allyn C. Howlett,Allyn C. Howlett,Christopher S. Breivogel,Steven R. Childers,Sam A. Deadwyler,Robert E. Hampson,Linda J. Porrino +6 more
TL;DR: Delta9-Tetrahydrocannabinol from Cannabis sativa is mimicked by cannabimimetic analogs such as CP55940 and WIN55212-2, and antagonized by rimonabant and SR144528, through G-protein-coupled receptors, CB1 in the brain, and CB2 in the immune system.
Journal ArticleDOI
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
Vincenzo Di Marzo,Christopher S. Breivogel,Qing Tao,David T. Bridgen,Raj K. Razdan,Anne M. Zimmer,Andreas Zimmer,Billy R. Martin +7 more
TL;DR: A ligand/receptor relationship between AEA and CB1 in these two brain regions, where tonic activation of the receptor may tightly regulate the biosynthesis of its endogenous ligand is suggested.
Journal Article
Activation of Cannabinoid Receptors in Rat Brain by WIN 55212-2 Produces Coupling to Multiple G Protein α-Subunits with Different Potencies
TL;DR: The results suggest that cannabinoid receptors activate multiple G proteins simultaneously in several brain regions and both the efficacy and potency of cannabinoid agonists to activate individual G(alpha) subunits may vary considerably.
Journal ArticleDOI
Basic neuroanatomy and neuropharmacology of cannabinoids
TL;DR: There is now evidence that manipulation of the endocannabinoid system could be a therapeutic target for a variety of conditions.
Journal ArticleDOI
Sensitivity to Δ9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-/- mice
TL;DR: It is demonstrated that &bgr;-arrestin2 may regulate cannabinoid CB1 receptor sensitivity in an agonist-specific manner.